FDA Orders Eye Risk Warning for GLP-1 Medications

The FDA is requiring new safety labeling for glucagon like peptide 1 receptor agonists, a class that includes approved medications such as Ozempic, Wegovy, Mounjaro, and Zepbound, after reviewing data pointing to a potential increased risk of a rare eye condition called non arteritic anterior ischemic optic neuropathy, or NAION, according to an FDA drug safety communication.

NAION can cause sudden, painless vision loss in one eye, sometimes noticed upon waking, along with blurred vision, blind spots, or distorted colors. The agency says it is caused by reduced blood flow to the optic nerve, though the exact mechanism is not fully understood. Risk factors include smoking, diabetes, high blood pressure, sleep apnea, anemia, and kidney disease.

The labeling change follows a 2024 published study on semaglutide and NAION, which prompted the FDA to review clinical trial data, animal data, and postmarketing reports. Across 126 randomized controlled trials, the agency found 6.4 NAION cases per 100,000 person years among GLP-1 RA users, compared with 3.8 per 100,000 among those on placebo or non GLP-1 glucose lowering drugs.

This is a labeling update for approved prescription drugs, not a new restriction on their use. The FDA advises patients to seek immediate care for sudden one sided vision changes and tells clinicians to consider stopping treatment if NAION develops, unless benefits clearly outweigh the risk.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.